MCM
NBIX icon

McKinley Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

McKinley Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-54,216
Closed -$5.21M – 197
2020
Q3 		$5.21M Sell
54,216
-99,884
-65% -$11.6M 0.41% 71
2020
Q2 		$18.8M Sell
154,100
-6,169
-4% -$682K 1.28% 23
2020
Q1 		$13.9M Sell
160,269
-1,492
-0.9% -$146K 1.11% 32
2019
Q4 		$17.4M Buy
161,761
+28,393
+21% +$2.97M 1.13% 34
2019
Q3 		$12M Sell
133,368
-13,617
-9% -$1.27M 0.9% 46
2019
Q2 		$12.4M Sell
146,985
-29,403
-17% -$2.41M 0.79% 44
2019
Q1 		$15.5M Buy
176,388
+3,710
+2% +$310K 1.12% 33
2018
Q4 		$12.3M Sell
172,678
-2,782
-2% -$267K 1% 37
2018
Q3 		$21.6M Buy
175,460
+48,562
+38% +$5.51M 1.37% 28
2018
Q2 		$12.5M Buy
126,898
+1,833
+1% +$164K 0.81% 45
2018
Q1 		$10.4M Sell
125,065
-13,759
-10% -$1.16M 0.61% 56
2017
Q4 		$10.8M Buy
+138,824
New +$9.47M 0.54% 57

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

McKinley Capital Management's NBIX Position: Q4 2020 in Review

McKinley Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 54,216 shares — an estimated $5.21M sold.

McKinley Capital Management first reported a position in NBIX in Q4 2017 and held it in 12 quarters. The position peaked at $21.6M in Q3 2018. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • McKinley Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • McKinley Capital Management sold 54,216 Neurocrine Biosciences shares in Q4 2020, an estimated $5.21M.
  • McKinley Capital Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 12 quarters.
  • McKinley Capital Management's Neurocrine Biosciences position peaked at $21.6M in Q3 2018.
  • 406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on McKinley Capital Management's 13F filing for Q4 2020, filed 10 Feb 2021.